Overview of QQ2 2025 key metrics (USD, unless noted):
- Revenue: not disclosed in the QQ2 2025 filing
- Gross Profit: -$162,309.00
- R&D Expenses: $3,429,479.00
- SG&A Expenses (Selling, General & Administrative): $1,681,844.00
- Other Expenses: -$2,500,000.00
- Operating Expenses (costs and expenses): $2,611,323.00
- EBIT/EBITDA: -$2,366,849.00 / EBITDA shows a loss of the same magnitude
- Operating Income: -$2,611,323.00
- Total Other Income/Expenses Net: $168,841.00
- Income Before Tax: -$2,442,482.00
- Net Income: -$2,442,482.00
- EPS (basic and diluted): -$0.12
- Weighted Average Shares Outstanding: 20,634,887
- Cash and Cash Equivalents at period end: $3,416,604
- Total Assets: $4,310,018
- Total Liabilities: $10,691,127
- Total Stockholders’ Equity: -$6,381,109
- Net Debt: -$3,058,860 (net cash position after rounding based on reported lines)
- Current Ratio: 0.384; Quick Ratio: 0.384; Cash Ratio: 0.357
Key YoY/QoQ context from the provided metrics:
- Gross Profit YoY: -109.19%; QoQ: 4.52%
- Operating Income YoY: 60.73%; QoQ: 66.37%
- Net Income YoY: 68.86%; QoQ: 68.78%
- EPS YoY: 78.57%; QoQ: 69.23%
Notes: Revenue is not disclosed in the QQ2 2025 filing, which constrains the interpretation of gross profit and margin metrics. The sizeable R&D expenditure and one-off or unusual items (as reflected in negative gross profit despite the lack of reported revenue) imply accounting or disclosure nuances; however, the financials clearly show a burn-focused profile typical of a development-stage biotech.